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Introduction: The rarity of thymomas and lack of multi-institutional 
studies have hampered therapeutic progress for decades. To overcome 
this, the members of the International Thymic Malignancy Interest 
Group created a worldwide retrospective database. This database was 
analyzed regarding the demographic and geographic distribution of thy-
momas and the impact of different variables on survival and recurrence.
Methods: This study analyzed 4221 thymomas diagnosed between 
1983 and 2012 with World Health Organization histotype infor-
mation from the International Thymic Malignancy Interest Group 
database. Associations to survival and recurrence were studied by 
univariate and multivariate analyses.
Results: Type B2 thymoma is the most common (28%) and type A the 
least common (12%) histotypes. They are significantly more frequent in 
Europe and the United States than Asia. Type A and AB occur at signifi-
cantly higher age than other thymomas (64 and 57 years, respectively). 
There are no differences in gender distribution. Stage is lower in type 
A (90% in stages I–II) and AB than B1 to B3 thymomas (38% of type 
B3 in stage III). In univariate analysis, recurrence is significantly less 
frequent among stage I/II tumors, in type A and AB (recurrence rates, 
1–2%) than B1 to B3 thymomas (2–7%). Multivariate analysis reveals 
an impact of age, stage, and resection status on survival and recurrence, 
whereas for histology there is only a significant impact on recurrence.
Conclusion: New findings are (1) geographic differences such as a 
lower incidence of type A and B2 thymoma in Asia; and (2) impact of 
stage and histology, the latter partially limited to early stage disease, 
on recurrence.
Key Words: Thymoma, International Thymic Malignancy Interest 
Group, World Health Organization histotype, Prognosis, Epidemiology.
(J Thorac Oncol. 2015;10: 367–372)
Thymomas and thymic carcinomas (TCs) are epithelial tumors of the thymus. They are the most frequent tumors 
of the anterior mediastinum in adults but account for less than 
1% of all human neoplasms. Thymomas comprise a spectrum 
of unique tumors of low to moderate malignant potential that 
are subdivided according to the histological classification of 
the World Health Organization (WHO) into type A, AB, B1, 
B3, and B3 and rare other subtypes. By contrast, TCs resem-
ble similarly termed carcinomas outside the mediastinum and 
usually follow an aggressive clinical course.1
The prognosis of thymomas and TCs seems to be mainly 
dependent on tumor stage and resection status, while the rele-
vance of WHO defined histological subtype as an independent 
prognostic marker among thymomas is still controversial: some 
studies and meta-analyses found a more favorable outcome of 
patients with type A, AB, and B1 compared with B2 and B3 
thymoma subtypes,2–6 whereas others did not.7,8 These controver-
sies are partly due to the rarity of these histologically complex 
tumors, and possibly, difficulties with interobserver reproduc-
ibility involving some subtypes of the WHO classification as 
suggested by discrepancies between relatively small published 
case series from different parts of the world.9 To overcome inher-
ent problems of previous small and mostly single-center series, 
and to identify true epidemiological and clinicopathological 
differences between thymoma patients across the globe, the 
International Thymic Malignancy Interest Group (ITMIG)10 has 
compiled a worldwide retrospective database of thymomas and 
TCs from small to large volume clinical and pathology centers in 
Asia, in the United States, and in Europe.11 Furthermore, ITMIG 
launched a worldwide, prospective, Internet-accessible clinico-
pathological database in 2012 (https://ccehubg.org/itmig).12
An overview of the ITMIG retrospective database has 
been published elsewhere,11 which includes original data 
from 4918 thymomas. The present article focuses on the thy-
moma cases in this database—specifically on those diagnosed 
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between 1983 and 2012 which included data on the WHO 
subtype and sufficient survival and recurrence data to be ger-
mane to an analysis of the impact of the WHO histotype of 
thymoma. An analysis of outcomes relative to WHO histotypes 
was beyond the scope of the retrospective database overview.12
This report addresses the following issues: (1) Are there 
demographic and clinical differences between the different 
histological thymoma subtypes? (2) Is the WHO histological 
classification consistently applied across different geographic 
regions, countries, and centers? (3) Which variables (WHO 
histotype, stage, resection status) affect survival? and (4) Does 
the WHO histotype have independent impact on prognosis?
MATERIALS AND METHODS
Of the 4918 thymomas in the ITMIG retrospective 
database,11 389 lacked histotype information and 308 were 
excluded due to diagnosis before 1983, leaving 4221 cases 
(Supplementary Table S1, SDC 1, http://links.lww.com/JTO/
A732). An additional 328 lacked sufficient epidemiological data 
and 26 were excluded due to being of tumor subtypes other than 
A to B3 (21 micronodular thymoma, 4 metaplastic thymoma, 
1 other). The overall survival (OS) analysis involved 2891 and 
the recurrence analysis 2408 patients after deleting cases with 
missing data (resection status, intervention date, follow-up date, 
etc.). Clinical centers were dichotomized by geographic region 
into low- and high-volume centers, high-volume centers being 
defined as the top contributors who submitted over 50% of all 
cases of a particular continent. This study was approved by the 
Yale Institutional Review Board (HIC # 1307012419).
Thymomas were classified according to WHO criteria13 
by local surgical pathologists. Tumors other than type A, B1, 
B2, B3, and AB thymomas were excluded. There was no cen-
tral review of slides for the purpose of this study.
Both the Masaoka et al.14 and the Masaoka-Koga15,16 
stage classification systems were used by submitting centers. 
Because the Thymic domain of the Staging and Prognostic 
Factors Committee found no difference in outcomes between 
these systems14–16 or between stages I and II,12,17 the Masaoka 
and Masaoka-Koga systems and stages I and II were com-
bined in the analysis in this article.
The ITMIG statistical core (XY, YD) performed all anal-
yses with SAS 9.3 (SAS Institute Inc., Cary, NC) and R. The 
primary outcome measures OS and cumulative incidence of 
recurrence (CIR) were analyzed using the Kaplan–Meier method 
and the log-rank test. Prognostic factors that were significantly 
associated with survival in univariate analysis (p < 0.05) were 
included in a Cox proportional hazards model for multivariate 
analysis. CIR was assessed using competing risk analysis, with 
death included as the competing event. The effect of clinical fac-
tors on recurrence was assessed using Gray’s test. All p values 
from pairwise comparisons were adjusted by using Bonferroni 
method due to multiple comparison problems. Statistical signifi-
cance was set at p less than 0.05 and all tests were two-tailed.
RESULTS
Patient Characteristics and Frequencies
Characteristics of the 4221 thymoma cases are sum-
marized in Supplementary Table S1 (SDC 1, http://links.lww.
com/JTO/A732). There is no gender predilection (49% male 
and 51% female patients). The largest number of cases came 
from centers in Europe; center volume ranged from 461 to 
2 patients. Demographic and clinical details specifically for 
each WHO histotype are shown in Table 1. There is no sig-
nificant gender predilection among the five WHO types. Type 
A and AB patients are significantly older than B1-3 patients 
(median, 60 versus 52, p < 0.0001). Myasthenia gravis (MG) 
is more frequent in type B1-3 thymomas (35–49%) than in 
type A and AB (25–26%). There is a significant association 
between WHO type and stage (p < 0.0001, Fig. 1).
There is remarkable variability in the proportion of WHO 
histotypes reported from individual centers: In Figure 2A, the cen-
ters are ordered by center volume to assess whether this is associ-
ated with center experience; no consistent trend is apparent. The 
results suggested a difference according to geographic regions; to 
assess this further, we grouped the centers according to the region 
(Fig. 2B). The frequency of type A thymoma is similar in Europe 
(15%) and the United States (14%), but significantly lower in Asia 
(6%, adjusted p < 0.0001). Type AB thymoma is more frequent 
in Asia (27%) than Europe (23%) and the United States (18%, 
adjusted p = 0.0002). Type B2 thymoma is similar in Europe 
(31%) and the United States (32%), but significantly lower in Asia 
(20%, adjusted p < 0.0001). Type B3 thymoma is more frequent 
in Asia (32%) than Europe (15%) and the United States (16%, 
adjusted p < 0.0001). The frequencies of type B1 thymoma (16–
20%) are not significantly different between geographic regions.
Survival and Recurrence
The OS probability is significantly different among the dif-
ferent WHO types (Supplementary Figure S1A, SDC 2, http://
links.lww.com/JTO/A733, R0 resected patients, p = 0.0165). 
However, there are no significant differences except that OS was 
significantly lower for B3 versus B1 (adjusted p = 0.043). CIR 
among R0 resected patients, all stages, is shown in Supplementary 
Figure S1B (SDC 2, http://links.lww.com/JTO/A733). The 5-year 
recurrence rate by histotype is as follows: type A 4% (95% confi-
dence interval [CI], 1–9%); type AB 2% (CI, 1–4%); type B1 8% 
(CI, 5–13%); type B2 13% (CI, 9–17%); and type B3 14% (CI, 
9–17%). For CIR, the differences are statistically significant with 
the exceptions that A and AB are almost identical, B2 and B3 are 
TABLE 1.  Clinical Characteristics of Each WHO Histotype
Thymoma 
Histotype N
% of 
Total % Male
Median 
Age (yr)
% With 
MG
Median 
Size (cm)
A 443 11 53 64 26 6.0
AB 891 23 48 57 25 6.5
B1 663 17 45 53 35 6.0
B2 1062 28 48 52 49 6.0
B3 808 21 53 52 40 6.0
MG, myasthenia gravis; WHO, World Health Organization.
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almost identical, and the difference between B3 versus B1 does 
not quite reach significance (adjusted p = 0.066). Of note, the OS 
of type A is relatively poor, whereas the recurrence rate for this 
histotype is quite low.
Association Between WHO Type 
and Other Prognostic Factors
The cohort under study in this article was examined for the 
effect of other known prognostic factors.18 Stage had a significant 
impact on OS among patients with thymoma (R0 resection, stages 
I + II versus III versus IVa versus IVb, p < 0.0001; Supplementary 
Figure S2A, SDC 3, http://links.lww.com/JTO/A734). All dif-
ferences are significant except that IVa is similar to IVb. There 
are also significant differences in CIR by stage (all thymoma his-
totypes, R0 resection, stages I + II versus III versus IVa versus 
IVb, p < 0.0001; Supplementary Figure S2B, SDC 3, http://links.
lww.com/JTO/A734). Resection status also proved to be a signifi-
cant prognostic factor among thymoma patients (Supplementary 
Figure S3, SDC 4, http://links.lww.com/JTO/A735).
The effect of WHO subtype on recurrence within each 
stage group in R0 resected patients is shown in Figure 3A–C, 
to eliminate the effect of stage and resection status (corre-
sponding data for survival are shown in Supplementary Figure 
S4, SDC 5, http://links.lww.com/JTO/A736). Thymoma histo-
type was a prognostic factor in stages I to II (1473 cases, R0); 
the CIR was significantly lower for type A, AB, and B2 versus 
B1 and B3 thymomas (5-year recurrence rates: type A 2%, 
[CI, 0.3–6%]; type AB 1% [0.4–3%]; B2 2% [0.8–4%] versus 
type B1 6% [3–10%]; and type B3 7% [3–12%]). By contrast, 
CIR was not significantly different between thymoma histo-
types within stages III (277 cases, R0) and IVa (89 cases, R0).
Multivariate Analysis
A multivariate analysis (including age, stage resection 
status, and WHO histotype) was conducted to ascertain the 
independent prognostic value of WHO subtype (Table 2). Age, 
stage, and resection status were all significantly associated 
with both OS and CIR by multivariate analysis. After adjust-
ing for age, stage, and resection status, WHO histology was 
not significantly associated with survival (p = 0.4); however, 
there was an association with recurrence (p < 0.04).
DISCUSSION
This is the first analysis of the impact of WHO histology, 
stage, and resection status on survival and recurrence in a large 
worldwide collection of patients. Our observation that type B2 
and AB are most common and type A the least common thy-
moma subtype is in agreement with findings in most previous 
studies.9,11,19,20 Furthermore, we confirmed associations of his-
totype with stage,7,21,22 age,2,7,20,21,23, and MG2,20,23 and a lack of 
association with gender9 from previous smaller studies.
Demographic and Clinical Characteristics 
of Thymoma Subtypes
We observed significant variability in the frequency 
distribution of histotypes at individual centers, which is also 
consistent with previous observations.9,23,24 These differences 
could be related to differences in institutional referral pat-
terns regarding age, MG, or earlier detection, given observed 
associations of these factors with thymoma histotype. The 
variability in histotype frequency does not seem to be a sim-
ple result of sampling error in a rare disease, given that the 
variability seems to be present among both higher and lower 
volume programs (Fig. 2). The observed variability in both 
high- and low-volume centers also argues that this is not due 
to pathologist inexperience; presumably, the case volume at 
high-volume institutions would provide adequate exposure. It 
is more likely that the variability reflects a lack of consistency 
in histotype classification. However, this study cannot directly 
evaluate this issue because central pathology review was not 
possible. ITMIG has proposed refinements to criteria for his-
totype classification in an effort to improve reproducibility.25,26
Variability in Frequency of Thymoma Subtypes
This is the first study investigating the distribution of 
histotypes across geographic regions in a large worldwide 
collection of patients. We observed a significantly lower fre-
quency of type A thymoma in Asia and the higher frequency 
of B2 thymomas in Europe. This seems to be a fairly con-
sistent finding across centers within a region, further arguing 
against this observation being due to chance alone. This could 
represent regional differences in histologic classification and 
interpretation; however, the phenomenon is observed even in 
high-volume centers, most of which have pathologists who 
received training in other geographic regions. It is possible 
that the regional differences represent epidemiologic differ-
ences as has been seen in a variety of cancers. Investigating 
the histotype distribution among migrant populations might 
help to distinguish genetic from environmental factors in 
disease etiology.27 At this point, the suggestion of a possible 
epidemiologic difference can only be viewed as speculative, 
requiring development of more reproducible diagnostic crite-
ria for histological subtyping26,28 and additional studies, per-
haps including central pathology review.29
FIGURE 1.  Stage distribution of thymoma histotypes. 
Stage classification as reported by the centers using either 
the Masaoka or Masoaka-Koga classification systems. WHO, 
World Health Organization.
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Impact of Thymoma Subtype on Outcomes
The discrepancy between the low recurrence rate for type A 
thymomas and the relatively lower survival rate is likely explained 
by the significantly higher median age for type A than for AB, 
B1, B2, and B3 thymomas (i.e., a greater proportion of thy-
moma-unrelated deaths). This underscores that recurrence may 
be a better marker of the biologic potential of thymoma.18 It also 
highlights the benefit of assessing both survival and recurrence 
together as in this study, in contrast to most previous studies that 
either focused on either survival2,21,23,24 or recurrence.6,30–32
This study confirms the strong prognostic value of 
stage, shown in many other smaller studies.7,20–22,32–38 We also 
confirmed the prognostic impact of resection status. The sub-
stantially larger size of the present study permitted a more 
robust multivariate analysis which demonstrated that both of 
these factors have independent prognostic significance.
FIGURE 2.  Relative frequency of thymoma histotypes by center volume and geographic region. A, Frequency of thymoma 
subtypes, ordered by size of center and geographic region. B, The frequency of thymoma subtypes by region and by high- and 
low-volume centers. “High volume centers” are those contributing more than 50% of the total cases per region. WHO, World 
Health Organization.
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The recurrence rate is strongly correlated with the 
histotype by univariate analysis, as has been shown in other 
smaller studies.2,20,22,35–39 However, it must be recognized that 
there is a strong association between stage and the histotype 
(Fig. 1). Indeed, in multivariate analysis there is no indepen-
dent prognostic impact of histotype on survival. An effect of 
histotype remains with respect to recurrence though. This 
effect seems to be limited to stages I + II and is only signifi-
cant for type AB versus B1, B2, or B3 thymoma. The lack of 
significant differences for type A versus the B subtypes, how-
ever, is likely due to the smaller number of type A patients 
because otherwise type A and AB seem to have the same 
results. Nevertheless, the fact that the independent prognostic 
value of histotype on recurrence in the large ITMIG database 
is limited to very specific patients (stages I + II, AB versus B 
subtypes) underscores that stage has a more profound prog-
nostic impact.
CONCLUSION
The ITMIG retrospective database provides an unprec-
edented opportunity to investigate the impact of thymoma 
histotypes in a large worldwide cohort. This has shown that 
the average age is higher in type A (and AB), MG is most 
commonly seen in the B subtypes (especially B2), and there 
is an increasingly higher proportion of higher stage disease 
moving from A/AB to B1, B2, and especially B3. Some vari-
ability exists in the proportion of histotypes at individual 
centers. There seems to be a lower proportion of type A thy-
moma in Asia and more type B2 in Europe for unclear rea-
sons. Although WHO histotype is associated with differences 
in survival and recurrence, a multivariate analysis shows that 
age, stage, and resection status have the greatest independent 
prognostic impact that WHO histotype is an independent 
prognostic factor in recurrence but not survival. The effect on 
recurrence is seen in stages I + II thymoma and for type AB 
versus B1, B2, and B3.
TABLE 2.  Multivariate Analysis for Survival and Recurrence
Overall Survival Recurrence
HR p HR p
Age 1.04 <0.0001 0.99 <0.02
WHO histology 0.4 <0.04
  AB vs. A 0.87 0.6 0.79 0.6
  B1 vs. A 0.63 0.1 1.27 0.6
  B2 vs. A 0.98 0.9 1.76 0.3
  B3 vs. A 0.94 0.8 1.26 0.6
Stage <0.0001 <0.0001
  III vs. I + II 2.15 <0.001 5.94 <0.0001
  IV vs. I + II 3.57 <0.0001 13.82 <0.0001
Resection status <0.0004 <0.0001
  R1 vs. R0 1.05 0.8 1.64 0.01
  R2 vs. R0 1.28 0.2 1.21 0.4
Results of multivariate analysis for survival and recurrence. Boldface highlights 
factors with p ≤ 0.05.
HR, hazard ratio; WHO, World Health Organization.
FIGURE 3.  Recurrence by thymoma histotype for specific 
stage groups. Cumulative incidence of recurrence by World 
Health organization (WHO) type (R0 patients) for (A) stages 
I + II, (B) stage III, and (C) stage IVa. Curves for stage IVb are 
not shown due to low case numbers. The table inserted in (A) 
shows pairwise comparisons for stages I + II with adjusted p 
values, asterisk denotes p ≤ 0.05. Data for stages III and IVa 
are not shown because all results are nonsignificant.
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